Levetiracetam in Generalized Social Anxiety Disorder: A Double-Blind, Randomized Controlled Trial
J Clin Psychiatry 2010;71(5):627-631
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: This multicenter, double-blind, placebo-controlled, 2-arm, parallel-group study was carried out to determine the effectiveness and safety of the novel anticonvulsant levetiracetam for the treatment of generalized social anxiety disorder (GSAD).
Method: After a 1-week, single-blind, placebo run-in period, 217 adult outpatients meeting
DSM-IV criteria for social anxiety disorder,
generalized type, were randomly assigned (1:1) to 12 weeks of double-blind treatment with either levetiracetam (n = 111) or placebo (n = 106). Participants were required to have scores of ≥ 60 on the Liebowitz Social Anxiety Scale (LSAS) and a total score of ≤ 17 on the 17-item Hamilton Depression Rating Scale (HDRS). The primary outcome measure was mean change from baseline on LSAS total score. Levetiracetam was initiated at 250 mg/d and flexibly titrated up to a maximum dose of 3,000 mg/d (1,500 mg bid). Dosage was held stable for the last 6 weeks of treatment. The study was conducted from September 2003 to June 2004.
Results: No statistically significant difference was found between the adjusted mean changes in LSAS score for levetiracetam (−24.4) and placebo (−28.7) using an efficacy intent-to-treat, last-
observation-carried-forward analysis. Rates of response (≥ 30% reduction in LSAS score) were similar with 41.3% (levetiracetam) and 46.6% (placebo). No significant between-group differences were found on secondary outcome measures, which included changes in Sheehan Disability Scale, Clinical Global Impression of Change,
and HDRS scores.
Conclusions: Although well-tolerated, levetiracetam failed to separate from placebo in this trial for the treatment of moderate to severe GSAD.
Submitted: December 12, 2008; accepted February 2, 2009.
Online ahead of print: December 15, 2009.
Corresponding author: Murray B. Stein, MD, MPH, Anxiety and Traumatic Stress Disorders Research Program, University of California
San Diego, 8939 Villa La Jolla Drive, Suite 200, La Jolla, CA 92037